For generation of a CML mouse model, KSL cells were infected for 2 days using a retrovirus with the use of CombiMag.
This paper demonstrated the high efficiency of Magnetofection from
OZ Biosciences
to enhance the infection and transduction in primary cells.
article reference: Cancer Cell. 2013 Mar 18;23(3):347-61.
Ablation of fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
Abstract
Imatinib eradicates dividing progenitor
cells of chronic myeloid
leukemia (CML) but does not effectively target nondividing
leukemia-
initiating cells
(LICs); thus, the disease often relapse after its discontinuation. We
now show that Fbxw7 plays a pivotal role in maintenance of
quiescence in LICs of CML by reducing the level of c-Myc. Abrogation of
quiescence
in LICs by Fbxw7 ablation increased their sensitivity to imatinib, and
the combination of Fbxw7 ablation with imatinib treatment resulted in a
greater depletion of LICs than of normal hematopoietic stem
cells in mice. Purging of LICs by targeting Fbxw7 to interrupt their
quiescence and subsequent treatment with imatinib may thus provide the basis for a promising therapeutic approach to CML.
CombiMag from OZ Biosciences is a very efficient transfection reagent based on Magnetofection™
technology.
No comments:
Post a Comment